Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.
Also called NCT06268977
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 482 participants
- Sponsor
- Registry
-
NCT06268977
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT06268977. Non-randomized; no masking; primary purpose treatment. Start 2025-04-01 (actual); primary completion 2026-01-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Assiut University
Record details
- Record id
cardio:ct-nct06268977- Content hash
6eb4f09ae82532b69b65717fca7af5c29d3b50c7c7fb990c12bb1162c43ea458